SCHEMBL20280313

SCHEMBL20280313

Cc1cc(N(C)C)cc(O)c1/N=N/c1ccccn1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 14/20 0.65
RIOK2 Q9BVS4 1/20 0.57
MAOA P21397 2/20 0.55
MAOB P27338 2/20 0.55
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 1/20 0.46
OPRK1 P41145 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5981718 0.79 KCNH2 (1.00) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL30374239 0.79 KCNH2 (1.00) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL31621739 0.79 KCNH2 (1.00) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL5981715 0.79 KCNH2 (1.00) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL20280234 0.78 KCNH2 (0.54) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL25658306 0.77 KCNH2 (0.72) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL20280175 0.75 LMNA (0.51) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL20280176 0.74 KCNH2 (0.64) KCNH2RIOK2MAOAMAOBLMNA
SCHEMBL407010 0.71 MAOA (1.00) KCNH2RIOK2MAOAMAOBNPC1
SCHEMBL407009 0.71 MAOA (1.00) KCNH2RIOK2MAOAMAOBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3347001-B1 AZOPHENOLS AS ERG ONCOGENE INHIBITORS HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC (US) 2023-07-26 EP disclosed
US-10238639-B2 Azophenols as ERG oncogene inhibitors THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2019-03-26 US disclosed
US-20180169074-A1 Azophenols as ERG Oncogene Inhibitors THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180169074-A1 Azophenols as ERG Oncogene Inhibitors ERG, ESR1, CBX2 KCNH2 3350/4885RIOK2 2127/4885MAOA 4156/4885
US-10238639-B2 Azophenols as ERG oncogene inhibitors ERG, ESR1, CBX2 KCNH2 3350/4885RIOK2 2127/4885MAOA 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.